本病例报告描述了 selpercatinib（一种选择性 RET 抑制剂）在具有 CCDC6::RET 融合的大细胞神经内分泌胰腺癌 (LCNEPAC) 的罕见病例中的疗效。在 LOXO-RET-17001 研究中，一名有多种系统治疗史的 56 岁男性在开始使用 selpercatinib 后不久就表现出明显的临床改善（ClinicalTrials.gov ID：NCT03157128，首次发布：2017-05-17）。来自患者智能手表的数据表明，在血清肿瘤标记物和 CT 成像等常规方法确认抗肿瘤活性之前，该药物已显示出早期疗效。该案例不仅强调了selpercatinib治疗RET融合阳性罕见肿瘤的功效，也凸显了可穿戴技术在癌症治疗中的潜力。总之，市售可穿戴设备的标准读数可用于监测对靶向治疗的治疗反应，并可作为临床试验中的数字生物标志物。这种方法标志着以患者为中心的医疗保健的重大进步，利用技术提高治疗评估的有效性和精确度。© 2024。作者。

This case report describes the efficacy of selpercatinib, a selective RET inhibitor, in an unusual case of large-cell neuroendocrine pancreatic carcinoma (LCNEPAC) harboring a CCDC6::RET fusion. A 56-year-old male with a history of multiple lines of systemic therapies exhibited marked clinical amelioration shortly after initiating selpercatinib within the LOXO-RET-17001 study (ClinicalTrials.gov ID: NCT03157128, first posted: 2017-05-17). Data from the patient's smartwatch suggested early efficacy before conventional methods, such as serum tumor markers and CT imaging confirmed the antitumor activity. This case not only underscores the efficacy of selpercatinib in treating RET fusion-positive rare tumors but also highlights the potential of wearable technology in cancer care. In conclusion, the standard readings from commercially available wearable devices can be useful for the monitoring of treatment response to targeted therapy and may serve as digital biomarkers in clinical trials. This approach marks a significant advancement in patient-centric healthcare, leveraging technology to enhance the effectiveness and precision of treatment evaluation.© 2024. The Author(s).